| Literature DB >> 26106601 |
Wajiha J Kheir1, Huda Sheheitli1, Maamoun Abdul Fattah1, Rola N Hamam1.
Abstract
Nontuberculous or atypical mycobacterial ocular infections have been increasing in prevalence over the past few decades. They are known to cause periocular, adnexal, ocular surface and intraocular infections and are often recalcitrant to medical therapy. These infections can potentially cause detrimental outcomes, in part due to a delay in diagnosis. We review 174 case reports and series on nontuberculous mycobacterial (NTM) ocular infections and discuss etiology, microbiology, risk factors, diagnosis, clinical presentation, and treatment of these infections. History of interventions, trauma, foreign bodies, implants, contact lenses, and steroids are linked to NTM ocular infections. Steroid use may prolong the duration of the infection and cause poorer visual outcomes. Early diagnosis and initiation of treatment with multiple antibiotics are necessary to achieve the best visual outcome.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26106601 PMCID: PMC4461732 DOI: 10.1155/2015/164989
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Distribution of reports of NTM infections over time.
Distribution of the types of ocular NTM infections.
| Type of infection | Number of eyes ( |
|---|---|
| Periocular and adnexal infections | |
| Orbital [ | 11 (2.6%) |
| Eyelid and periocular skin [ | 28 (6.7%) |
| Lacrimal system [ | 17 (4.0%) |
| Total |
|
| Ocular surface infections | |
| Keratitis [ | 290 (69.0%) |
| Scleritis [ | 18 (4.3%) |
| Conjunctivitis [ | 3 (0.7%) |
| Total |
|
| Intraocular infections and uveitis | |
| Endophthalmitis [ | 44 (10.4%) |
| Choroiditis [ | 6 (1.5%) |
| Iridocyclitis [ | 1 (0.2%) |
| Panuveitis [ | 2 (0.5%) |
| Total |
|
NTM species in ocular infections.
| Mycobacterial species | Number of Eyes
|
|---|---|
|
| 179 (42.6%) |
|
| 62 (14.8%) |
|
| 46 (11.0%) |
|
| 8 (1.9%) |
|
| 8 (1.9%) |
|
| 4 (1.0%) |
|
| 4 (1.0%) |
|
| 4 (1.0%) |
|
| 3 (0.7%) |
|
| 3 (0.7%) |
|
| 3 (0.7%) |
|
| 2 (0.5%) |
|
| 2 (0.5%) |
|
| 1 (0.2%) |
|
| 1 (0.2%) |
|
| 1 (0.2%) |
|
| 1 (0.2%) |
|
| 1 (0.2%) |
|
| 1 (0.2%) |
|
| 1 (0.2%) |
|
| 1 (0.2%) |
|
| 84 (20.0%) |
Summary of the results specific to location of infection.
| Location of NTM infections | Total cases | Etiology | Medical treatment | Surgical treatment | Outcomes |
|---|---|---|---|---|---|
| Orbital infections | 11 | (i) Orbital reconstruction/Fracture repair 4/11 (36.4%) | Systemic ATB combination | Excision of lesion | (i) Resolution |
|
| |||||
| Eyelid/periocular skin infections | 28 | (i) Ptosis Repair and/or Blepharoplasty | Systemic ATB combination | (i) Excision/incision and drainage/debridement | (i) Resolution |
|
| |||||
| Lacrimal system infections | 17 | (i) Implants | Topical + systemic | Removal of implant | (i) Resolution |
|
| |||||
| Keratitis | 290 | (i) LASIK | (i) Topical | (i) Removal of | (i) Resolution |
|
| |||||
| Scleritis | 18 | Scleral buckling | Topical | Explanation of buckle | (i) Resolution |
|
| |||||
| Endophthalmitis | 44 | Cataract surgery (IOL insertion) | (i) Intraocular + topical/systemic/periocular | PPV | (i) Resolution |
|
| |||||
| Uveitis | 9 | HIV/AIDS | Systemic/topical + systemic | (i) PPV | (i) Resolution |
Denominator differs from total number of cases due to missing data.
*Analysis was done based on infections that led to eventual resolution without loss of vision.
Medical treatment of NTM keratitis.
| Mode of delivery | Number of eyes |
|---|---|
| Topical | 108 (53.2%) |
| Topical and systemic | 85 (41.9%) |
| Systemic | 5 (2.5%) |
| Topical, systemic, and periocular | 2 (1%) |
| Topical and intraocular | 1 (0.5%) |
| Topical and periocular | 1 (0.5%) |
| Systemic and periocular | 1 (0.5%) |
|
| |
| Antibiotic (ATB) regimen | Number of eyes |
|
| |
| Amikacin alone | 56 (29.2%) |
| Amikacin + macrolide | 27 (14.1%) |
| Amikacin + fluoroquinolone | 24 (12.5%) |
| Amikacin + fluoroquinolone + macrolide | 18 (9.4%) |
| Fluoroquinolone + macrolide | 16 (8.3%) |
| Other* | 14 (7.3%) |
| Fluoroquinolone alone | 13 (6.8%) |
| Amikacin + 1 or more ATB* | 11 (5.7%) |
| Macrolide + 1 or more ATB* | 7 (3.6%) |
| Macrolide alone | 5 (2.6%) |
| Fluoroquinolone + 1 more ATB* | 1 (0.5%) |
*Antibiotic not including amikacin/fluoroquinolone/macrolide.